Pathways Responsible for Human Autoantibody and Therapeutic Intravenous IgG Activity in Humanized Mice
Immunoglobulin G (IgG) antibodies are major drivers of autoimmune pathology, but they are also used in the form of intravenous IgG (IVIg) therapy to suppress autoantibody activity. To identify the pathways underlying human autoantibody and IVIg activity, we established a humanized mouse model of an...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2015-10-01
|
Series: | Cell Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211124715010244 |
id |
doaj-b93f2610da2b40a3a73e8f64bc13f7d1 |
---|---|
record_format |
Article |
spelling |
doaj-b93f2610da2b40a3a73e8f64bc13f7d12020-11-24T21:54:51ZengElsevierCell Reports2211-12472015-10-0113361062010.1016/j.celrep.2015.09.013Pathways Responsible for Human Autoantibody and Therapeutic Intravenous IgG Activity in Humanized MiceInessa Schwab0Anja Lux1Falk Nimmerjahn2Institute of Genetics at the Department of Biology, Friedrich Alexander University Erlangen-Nürnberg, Erwin-Rommel-Straβe 3, 91058 Erlangen, GermanyInstitute of Genetics at the Department of Biology, Friedrich Alexander University Erlangen-Nürnberg, Erwin-Rommel-Straβe 3, 91058 Erlangen, GermanyInstitute of Genetics at the Department of Biology, Friedrich Alexander University Erlangen-Nürnberg, Erwin-Rommel-Straβe 3, 91058 Erlangen, GermanyImmunoglobulin G (IgG) antibodies are major drivers of autoimmune pathology, but they are also used in the form of intravenous IgG (IVIg) therapy to suppress autoantibody activity. To identify the pathways underlying human autoantibody and IVIg activity, we established a humanized mouse model of an autoantibody-dependent autoimmune disease responding to treatment with IVIg preparations. We show that the human IgG subclass strongly impacts autoantibody activity and that the Fc-receptor genotype of the human donor immune system further modulates autoantibody activity. Human mononuclear phagocytes were responsible for autoantibody activity, and IVIg therapy was able to suppress disease pathology in an Fc-fragment-dependent manner. While highly sialylated IgG glycovariants were essential for IVIg activity, it was independent of the Fc-receptor genotype and did not result in a general block of activating or the neonatal Fc-receptor. These findings may help in the development of strategies to block autoantibody and enhance therapeutic IVIg activity in humans.http://www.sciencedirect.com/science/article/pii/S2211124715010244 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Inessa Schwab Anja Lux Falk Nimmerjahn |
spellingShingle |
Inessa Schwab Anja Lux Falk Nimmerjahn Pathways Responsible for Human Autoantibody and Therapeutic Intravenous IgG Activity in Humanized Mice Cell Reports |
author_facet |
Inessa Schwab Anja Lux Falk Nimmerjahn |
author_sort |
Inessa Schwab |
title |
Pathways Responsible for Human Autoantibody and Therapeutic Intravenous IgG Activity in Humanized Mice |
title_short |
Pathways Responsible for Human Autoantibody and Therapeutic Intravenous IgG Activity in Humanized Mice |
title_full |
Pathways Responsible for Human Autoantibody and Therapeutic Intravenous IgG Activity in Humanized Mice |
title_fullStr |
Pathways Responsible for Human Autoantibody and Therapeutic Intravenous IgG Activity in Humanized Mice |
title_full_unstemmed |
Pathways Responsible for Human Autoantibody and Therapeutic Intravenous IgG Activity in Humanized Mice |
title_sort |
pathways responsible for human autoantibody and therapeutic intravenous igg activity in humanized mice |
publisher |
Elsevier |
series |
Cell Reports |
issn |
2211-1247 |
publishDate |
2015-10-01 |
description |
Immunoglobulin G (IgG) antibodies are major drivers of autoimmune pathology, but they are also used in the form of intravenous IgG (IVIg) therapy to suppress autoantibody activity. To identify the pathways underlying human autoantibody and IVIg activity, we established a humanized mouse model of an autoantibody-dependent autoimmune disease responding to treatment with IVIg preparations. We show that the human IgG subclass strongly impacts autoantibody activity and that the Fc-receptor genotype of the human donor immune system further modulates autoantibody activity. Human mononuclear phagocytes were responsible for autoantibody activity, and IVIg therapy was able to suppress disease pathology in an Fc-fragment-dependent manner. While highly sialylated IgG glycovariants were essential for IVIg activity, it was independent of the Fc-receptor genotype and did not result in a general block of activating or the neonatal Fc-receptor. These findings may help in the development of strategies to block autoantibody and enhance therapeutic IVIg activity in humans. |
url |
http://www.sciencedirect.com/science/article/pii/S2211124715010244 |
work_keys_str_mv |
AT inessaschwab pathwaysresponsibleforhumanautoantibodyandtherapeuticintravenousiggactivityinhumanizedmice AT anjalux pathwaysresponsibleforhumanautoantibodyandtherapeuticintravenousiggactivityinhumanizedmice AT falknimmerjahn pathwaysresponsibleforhumanautoantibodyandtherapeuticintravenousiggactivityinhumanizedmice |
_version_ |
1725865284365975552 |